|
Teprasiran
|
DB15064 |
[Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).] |
|
Volanesorsen
|
DB15067 |
[Volanesorsen is under investigation in clinical trial NCT02639286 (Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension).] |
|
Givosiran
|
DB15066 |
[Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway.[L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity.[L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases.[A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders.] |
|
Lefitolimod
|
DB15061 |
[Lefitolimod is under investigation in clinical trial NCT03837756 (Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV).] |
|
Inarigivir soproxil
|
DB15063 |
[Inarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).] |
|
Inarigivir
|
DB15062 |
[Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).] |
|
[Methylseleno]Acetate
|
DB03098 |
|
|
5-Amino 6-Nitro Uracil
|
DB03099 |
|
|
N-Aminoethylmorpholine
|
DB03096 |
|
|
PMP-hydroxyisoxazole, pyridoxamine-5-phosphate-hydroxyisoxazole
|
DB03097 |
|
|
3,5-Dihydro-5-Methylidene-4h-Imidazol-4-On
|
DB03094 |
|
|
Tetramethylammonium Ion
|
DB03095 |
|
|
5-Hydroxymethyl-Chonduritol
|
DB03092 |
|
|
8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
|
DB03093 |
|
|
Ethylaminobenzylmethylcarbonyl Group
|
DB03090 |
|
|
4-Amido-4-Carbamoyl-Butyric Acid
|
DB03091 |
|
|
Troriluzole
|
DB15079 |
[Troriluzole is under investigation in clinical trial NCT03701399 (Troriluzole in Adult Subjects With Spinocerebellar Ataxia).] |
|
Abrilumab
|
DB15076 |
[Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).] |
|
4-demethyl-4-cholesteryloxycarbonylpenclomedine
|
DB15075 |
[4-demethyl-4-cholesteryloxycarbonylpenclomedine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).] |
|
Rogaratinib
|
DB15078 |
[Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).] |
